U.S. market Open. Closes in 5 hours 14 minutes

TGTX | TG Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 36.50 - 39.61
52 Week Range 12.93 - 43.32
Beta 2.32
Implied Volatility 64.72%
IV Rank 50.28%
Day's Volume 3,626,938
Average Volume 2,641,247
Shares Outstanding 157,071,000
Market Cap 6,193,309,530
Sector Healthcare
Industry Biotechnology
IPO Date 2010-05-03
Valuation
Profitability
Growth
Health
P/E Ratio 262.87
Forward P/E Ratio -6.00
EPS 0.15
1YR Price Target 19.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 319
Country USA
Website TGTX
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.
*Chart delayed
Analyzing fundamentals for TGTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is passable. For more detailed analysis please see TGTX Fundamentals page.

Watching at TGTX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on TGTX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙